Showing 34,870 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

Finance & funding

US HIV funding decisions on PEPFAR in 2017 will have critical effect on ability to reach 90-90-90 goals

News
1 August 2017
Hepatitis B

Hepatitis B added to routine baby injections

Editor's pick
BBC News
1 August 2017
New & experimental HIV treatments

First protease inhibitor combination pill maintains viral suppression

News
1 August 2017
Pregnancy and vertical transmission

Adolescents with HIV do better in more prosperous African countries, even with treatment

News
31 July 2017
Hepatitis C treatment

Australia leads the world in hepatitis C treatment – what's behind its success?

Editor's pick
The Conversation AU
31 July 2017
Resistance

A massive second global wave of AIDS is coming — perhaps within the next 10 years

Editor's pick
Business Insider
31 July 2017
Hepatitis C treatment

Substantial fall in Hepatitis C rates in Canberra's jail with new treatments

Editor's pick
The Canberra Times
31 July 2017
Hepatitis C treatment

Hepatitis C patients unable to get drugs due to funding problems

Editor's pick
Irish Times
31 July 2017
PrEP

Customs seizing large amounts of anti-HIV drug being ordered online

Editor's pick
Irish Times
31 July 2017
HIV testing policies & guidelines

HIV tests for GPs' new patients could save lives and money, says study

Editor's pick
The Guardian
31 July 2017
New & experimental hepatitis C treatment

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

Editor's pick
AbbVie press release
31 July 2017
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C

Editor's pick
Gilead press release
31 July 2017
Chemsex & recreational drug use

Don’t Believe the Hype: The New Drugs Strategy Ignores the LGBT Community

Editor's pick
Vice
29 July 2017
PrEP

France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic

News
28 July 2017
PrEP programmes & uptake

Dutch study finds out whether gay men prefer daily or on-demand PrEP

News
28 July 2017
Hepatitis C treatment

From chronic to cured: could Australia be the first country in the world to eliminate hep C?

Editor's pick
Kirby Institute
28 July 2017
PrEP

Philippines trials anti-HIV drug as cases hit record high

Editor's pick
Thomson Reuters
27 July 2017
Global health targets

HIV treatment: Strategies to reach the next 10 million patients

Editor's pick
Devex
27 July 2017
Side effects

New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment

Editor's pick
Napo Pharmaceuticals press release
27 July 2017
Vaginal rings & topical PrEP

Dapivirine vaginal ring safe, acceptable for HIV prevention in teens

Editor's pick
Healio
27 July 2017
Self-testing & home testing

IAS 2017: UNITAID, partners boost HIV self-test access in six African countries

Editor's pick
Science Speaks
27 July 2017
Pregnancy and vertical transmission

Vertical HIV transmission may be influenced by complex synergies with other STI – such as Cytomegalovirus

Editor's pick
BMJ Group blogs
27 July 2017
Hepatitis & HIV

ECDC estimate: Around 9 million Europeans are affected by chronic hepatitis B or C

Editor's pick
Eurekalert Inf Dis
27 July 2017
Vaginal rings & topical PrEP

Rectal products for PrEP: Are they an option?

Editor's pick
BETA blog
27 July 2017